What is PFE stock?

PFE stock is the ticker symbol for Pfizer Inc., a global pharmaceutical company whose shares trade on the New York Stock Exchange. Investors use this ticker to access a business that generates more than $60 billion in annual revenue from vaccines, oncology therapies and other prescription medicines worldwide.[2]

Following a surge tied to its COVID-19 products, Pfizer’s share price has retreated and now trades in the mid‑$20 range, significantly below the all‑time high above $61 reached in late 2021.[1][2] This shift marks a transition from a pandemic‑driven growth story to a period in which markets focus on the durability of Pfizer’s broader pipeline and earnings power.

Current performance and dividend profile

Recent performance data show that PFE has declined in value over the past year, with a negative double‑digit percentage return, even though the stock has risen modestly over the most recent month.[1][2][3] The stock’s market capitalization remains around the mid‑$130 billion mark, underscoring Pfizer’s position as a large‑cap global healthcare leader despite the share price pullback.[1][2]

From a valuation standpoint, Pfizer’s trailing P/E ratio sits in the low‑teens, supported by billions in net income on more than $60 billion of annual revenue.[2] The company pays a sizable dividend, and current data indicate a yield of nearly 7%, which is notably higher than the broader market and a key part of the PFE investment case for income‑oriented shareholders.[2]

Outlook and analyst views on PFE

Analyst forecasts for PFE stock suggest a wide range of possible outcomes over the next 12 months, with price targets running from roughly the mid‑$20s to the mid‑$30s per share.[2] This dispersion reflects uncertainty over how quickly Pfizer can replace fading COVID‑19 product revenue with contributions from new drug launches, acquisitions and its late‑stage development pipeline.

Trading data highlight both active investor interest and moderate volatility: daily volumes frequently reach tens of millions of shares, while Pfizer’s one‑year beta remains below 1, indicating that PFE is less volatile than the overall market.[1][2][3] For investors, the central question is whether the current combination of a depressed share price, high dividend yield and solid but evolving fundamentals makes PFE stock an attractive long‑term value opportunity.